Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To provide additional clinical evidence in regulatory submissions for a modified-release (MR) once-daily (QD) tofacitinib formulation, we compared real-world adherence and effectiveness betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B., Greenberg, Jeffrey D., Harnett, James, Madsen, Ann, Smith, Timothy W., Gruben, David, Zhang, Richard, Lukic, Tatjana, Woolcott, John, Dandreo, Kimberly J., Litman, Heather J., Blachley, Taylor, Lenihan, Anne, Chen, Connie, Rivas, Jose L., Dougados, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854470/
https://www.ncbi.nlm.nih.gov/pubmed/33034006
http://dx.doi.org/10.1007/s12325-020-01501-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854470/
https://www.ncbi.nlm.nih.gov/pubmed/33034006
http://dx.doi.org/10.1007/s12325-020-01501-z

Ejemplares similares